The Newborn Screening Program in Italy: Comparison with Europe and other Countries
e202101007
Keywords:
Mass-tandem spectrometry, Neonatal screening, Inherited metabolic diseases, Diagnostic confirmationAbstract
In Italy, since 2016, extended neonatal screening has been mandatory throughout the country for about 40 inherited metabolic diseases. The law contains indications on: the list of pathologies, the information and consent, the methods of collecting and sending samples, the newborn screening system with the elements of its organization, appointed to guarantee the entire path of newborn screening, from the level I test to taking charge of the confirmed positive newborn, the communication and recall procedures for diagnostic confirmation and patient management, training and information initiatives, as well as the criteria for allocating the allocation.
Extended neonatal screening has introduced new issues in diagnosis, choice of decision levels, and metabolic disease panels to screen. Of particular relevance in order to a strong reduction of false positives, was the introduction of the second-tier test for some diseases such as leucinosis, isovaleric acidemia, methylmalonic aciduria. As regards the diseases to be screened, the Italian situation differs greatly from what happens in Europe where in the majority of member states there is no legislation / law governing this preventive pediatric service; screening is almost always on a voluntary basis (with the collection of written informed consent from both parents) and applied on the basis of health guidelines or recommendations. In the world, the most complete panel is the US one (RUSP, Recommended Uniform Screening Panel) which currently contains 62 pathologies, 35 of which are defined as core panels and 27 as secondary panels. As the name implies, it is a panel that the US Health Resources and Services Administration –HRSA– recommends that it be applied by every State and that includes new screening in some areas including Pompe disease and MPS I, creatine deficiency. In conclusion, extended neonatal screening represents a real revolution in the metabolic field offering newborns an early diagnosis combined with effective therapeutic treatments capable of radically changing the course of these serious diseases.
Downloads
References
Levy HL, 1998: Newborn screening by tandem mass spectrometry (MS-MS). Clinical Chemistry, 44,
–2402.
Millington DS, Kodo N, Norwood DL, Roe CR, 1990: Tandem mass spectrometry: A new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. Journal of Inherited Metabolic Disease., 13, 321–324.
https://www.trovanorme.salute.gov.it/norme/dettaglioAtto?id=55762
Taruscio D, Kodra Y, Maria A, Amicosante V, Bacco G, Battilomo S, Burlina A, Privitera MG, la Marca G, Leonardi A, Salvatore F, Segato A, Vaccarotto M, Del Favero A, 2019: Screening neonatale esteso in Italia: stato dell’arte al 30 settembre 2018. Strumenti di riferimento, S2.
https://www.simmesn.it/it/rapporti-tecnici-screening-neonatale.html
Rinaldo P, Lim J, Tortorelli S, Gavrilov D, Matern D, 2008: Newborn screening of metabolic disorders: Recent progress and future developments. Nestle Nutrition Workshop Series: Pediatric Program., 62, 81–93.
McHugh DM, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Ahmed Al Nuaimi S, Åhlman H, Allen JJ, Antonozzi I, Archer S, Au S, Auray-Blais C, Baker M, Bamforth F, Beckmann K, Bentz Pino G, Berberich SL, Binard R, Boemer F et al, 2011: Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project. Genetics in Medicine., 13, 230–254.
Marquardt G, Currier R, McHugh DMS, Gavrilov D, Magera MJ, Matern D, Oglesbee D, Raymond K, Rinaldo P, Smith EH, Tortorelli S, Turgeon CT, Lorey F, Wilcken B, Wiley V, Greed LC, Lewis B, Boemer F, Schoos R et al, 2012: Enhanced interpretation of newborn screening results without analyte cutoff values. Genetics in Medicine., 14, 648–655.
Hewlett J, Waisbren SE, 2006: A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. Journal of Inherited Metabolic Disease., 29, 677–682.
Burlina AB, Polo G, Rubert L, Gueraldi D, Cazzorla C, Duro G, Salviati L, Burlina AP, 2019: Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy. International Journal of Neonatal Screening., 5, 24.
Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, Baker M, Ballow M, Bartoshesky LE, Bonilla FA, Brokopp C, Brooks E, Caggana M, Celestin J, Church JA, Comeau AM, Connelly JA, Cowan MJ, Cunningham-Rundles C et al, 2014: Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA - Journal of the American Medical Association., 312, 729–738.
Argudo-Ramírez A, Martín-Nalda A, Marín-Soria JL, López-Galera RM, Pajares-García S, González de Aledo-Castillo JM, Martínez-Gallo M, García-Prat M, Colobran R, Riviere JG, Quintero Y, Collado T, García-Villoria J, Ribes A, Soler-Palacín P, 2019. First Universal Newborn Screening Program for Severe Combined Immunodeficiency in Europe. Two-Years’ Experience in Catalonia (Spain). Frontiers in immunology, 10, 2406.
Puck JM, 2019: Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunological Reviews., 287, 241–252.
la Marca G, Giocaliere E, Malvagia S, Funghini S, Ombrone D, Della Bona ML, Canessa C, Lippi F, Romano F, Guerrini R, Resti M, Azzari C, 2014: The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis., 88, 201–206.
la Marca G, Giocaliere E, Malvagia S, Villanelli F, Funghini S, Ombrone D, Della Bona M, Forni G, Canessa C, Ricci S, Romano F, Guerrini R, Resti M, Azzari C, 2016: Development and validation of a 2nd tier test for identification of purine nucleoside phosphorylase deficiency patients during expanded newborn screening by liquid chromatography-tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine, 54, 627–632.
Parenti G, Pignata C, Vajro P, Salerno M, 2013: New strategies for the treatment of lysosomal storage diseases (Review). International Journal of Molecular Medicine., 31, 11–20.
Gelb M, 2018: Newborn Screening for Lysosomal Storage Diseases: Methodologies, Screen Positive Rates, Normalization of Datasets, Second-Tier Tests, and Post-Analysis Tools. International Journal of Neonatal Screening., 4, 23.
Burlina AB, Polo G, Salviati L, Duro G, Zizzo C, Dardis A, Bembi B, Cazzorla C, Rubert L, Zordan R, Desnick RJ, Burlina AP, 2018: Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. Journal of Inherited Metabolic Disease., 41, 209–219.
Donati MA, Pasquini E, Spada M, Polo G, Burlina A, 2018: Newborn screening in mucopolysaccharidoses. Italian journal of pediatrics., 44, 126.
Tortorelli S, Eckerman JS, Orsini JJ, Rinaldo P, Matern D, Gavrilov D, Alexander JJ, Stevens C, Oglesbee D, Hall PL, Hart J, Raymond K, 2017: Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease. Genetics in Medicine., 20, 840–846.
Rashed MS, Rahbeeni Z, Ozand PT, 1999: Application of electrospray tandem mass spectrometry to neonatal screening. Seminars in Perinatology.
https://www.abs.gov.au/population
Wilcken B, Wiley V, Hammond J, Carpenter K, 2003: Screening newborns for inborn errors of metabolism by tandem mass spectrometry. New England Journal of Medicine, 348, 2304–2312.
https://www.hgsa.org.au/documents/item/29
https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html
Scott CR, Elliott S, Hong X, Huang JY, Kumar AB, Yi F, Pendem N, Chennamaneni NK, Gelb MH, 2019: Newborn Screening for Mucopolysaccharidoses: Results of a Pilot Study with 100 000 Dried Blood Spots. Journal of Pediatrics., 216, 204–207.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Giancarlo la Marca
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
